No Data
No Data
Express News | Can-Fite BioPharma's Namodenoson Shows Potential To Stabilize Advanced Liver Cirrhosis, Offering New Hope Amid Limited Treatment Options
Disappearance of Decompensated Liver Cirrhosis Episodes After Treatment With Can-Fite's Namodenoson
Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025
US Patent Office Granted Can-Fite Namodenoson Patent for Use as Anti-Obesity Drug
Catalyst Watch: Netflix Earnings, Monster Beverage Event, Drug Data, and Quantum Volatility
D. Boral Capital Maintains Can-Fite BioPharma(CANF.US) With Buy Rating, Maintains Target Price $10